Reduction in Use of Cyproterone/Ethinylestradiol (Diane-35 and Generics) After Risk Minimization Measures in the Netherlands, UK and Italy
- Autori: Penning-van Beest FJ, Bezemer ID, Smits E, García Rodríguez LA, Cea Soriano L, Lapi F, Simonetti M, Asiimwe A, Herings RM.
- Published: 2020 May 26
- Rivista: Contraception.;S0010-7824(20)30158-X. doi: 10.1016/j.contraception.2020.05.010
- Link pubblicazione
Abstract
Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications.
Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy.
Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time.
Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.
